What are you looking for today?

Holida, Myrl, Linhart, Aleš, Longo, Nicola, Wallace, Eric, Tøndel, Camilla, Hughes, Derralynn, Warnock, David G., Pisani, Antonio, Eyskens, François, Deegan, Patrick, Feldt-Rasmussen, Ulla, Goker-Alpan, Ozlem, Mehta, Ankit, Piotti, Giovanni, Fichera, Vito, Wang, Meng, Chertkoff, Raul, Waldek, Stephen, Wilcox, William R. and Bernat, John A. (2026) Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. Orphanet Journal of Rare Diseases, 21 (1): 185. p. 185. ISSN 1750-1172

Document

Abstract

Abstract

Background: Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W). BRIGHT F51 (NCT03614234) is an ongoing phase III, open-label extension study evaluating long-term efficacy and safety of pegunigalsidase alfa 2 mg/kg E4W in adults with Fabry disease previously treated with agalsidase alfa or beta E2W for ≥ 3 years who completed one year of pegunigalsidase alfa treatment in the BRIGHT study. This interim analysis reports results following 3–5 years of treatment (cutoff date December 31, 2022). Results: Twenty-nine patients were enrolled. Median (interquartile range [IQR]) annualized eGFR slope during treatment was ‒2.2 (‒2.9; ‒1.1) mL/min/1.73 m2/year (males: ‒2.4 [‒2.9; ‒1.0, n = 23]; females: ‒1.8 [‒2.4; ‒1.3, n = 6]; anti-drug antibody [ADA]-positive: ‒2.6 [‒4.0; ‒1.7, n = 9 all male]; ADA-negative: ‒1.8 [‒2.7; ‒0.6, n = 20]). Median (IQR) change in plasma lyso-Gb3 from baseline to Week 208 was 3.2 (‒3.9; 8.5, n = 17) nM in males; concentrations remained low and stable in females. Overall, 51/477 treatment-emergent adverse events in 13 patients (45%) were considered treatment-related (all mild/moderate). Nine patients (31%) experienced mild/moderate infusion-related reactions. One patient developed transient de novo ADAs. Conclusions: Long-term treatment with pegunigalsidase alfa 2 mg/kg E4W was well-tolerated and maintained disease stability, especially in females and ADA-negative males; more data are needed to better understand outcomes in ADA-positive males. Clinical outcomes should be closely monitored during E4W treatment. The final results of this extension study will further assess the feasibility of this dosing regimen. Trial registration details: ClinicalTrials.gov, NCT03614234. Registered July 30, 2018; https://clinicaltrials.gov/study/NCT03614234. Graphical Abstract:

Item Type: Article
Uncontrolled Keywords: Fabry disease, eGFR, Lysosomal storage disorders, Open-label extension, Enzyme replacement therapy, Pegunigalsidase alfa
Related URLs:
SWORD Depositor: Publication Router
Depositing User: Publication Router
URI: https://sure.sunderland.ac.uk/id/eprint/20224

Further Details

More Information

Uncontrolled Keywords
Fabry disease, eGFR, Lysosomal storage disorders, Open-label extension, Enzyme replacement therapy, Pegunigalsidase alfa
SWORD Depositor
Depositing User

Identifiers

Item ID
20224
Identification Number
ISSN
1750-1172

Users with ORCIDS

ORCID for John A. Bernat

Catalogue record

Date Deposited
11 May 2026 10:29
Last Modified
11 May 2026 10:29

Contributors

Author
Myrl Holida
Author
Aleš Linhart
Author
Nicola Longo
Author
Eric Wallace
Author
Camilla Tøndel
Author
Derralynn Hughes
Author
David G. Warnock
Author
Antonio Pisani
Author
François Eyskens
Author
Patrick Deegan
Author
Ulla Feldt-Rasmussen
Author
Ozlem Goker-Alpan
Author
Ankit Mehta
Author
Giovanni Piotti
Author
Vito Fichera
Author
Meng Wang
Author
Raul Chertkoff
Author
Stephen Waldek
Author
William R. Wilcox

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)

Downloads per month over past year